Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.
The new saw: Development-stage biotechs are maturing. Their drugs are winning approvals and independent commercial launches ...
Is the biotech industry truly out of its slump? This week on "The Readout LOUD," a biotech year in review and a look ahead to ...
Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...
TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of Adjusted EBITDA(1) positive operations in Q3 2025 and expects to achieve strong ...
It’s the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy.
XBI is a biotech-focused ETF offering equal-weight exposure to U.S. biotechnology companies. The SPDR S&P Biotech ETF tracks the performance of the S&P Biotechnology Select Industry Index. XBI ...
This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Alex Ossola: U.S. hiring slowed in January, but remained solid in the last jobs ...
A 2025 report from a bipartisan, congressionally chartered commission warns that China is closing in on a win, and the United ...
Hosted on MSN
Is It Time to Buy Biotech Stocks?
In this podcast, Motley Fool analysts Tim Beyers and Karl Thiel discuss: To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. When you're ready to invest, check ...
And what a year it has been! Artificial intelligence is being incorporated into more aspects of our lives, weight-loss drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback